Drug data last refreshed 3d ago
STRATTERA (atomoxetine HCl) is an oral small-molecule norepinephrine reuptake inhibitor approved for ADHD and explored across multiple neuropsychiatric indications. It works by selectively inhibiting the pre-synaptic norepinephrine transporter, increasing norepinephrine availability in the brain. The drug is indicated for ADHD, oppositional defiant disorder, reading disorder, social anxiety disorder, and depressive symptoms, with emerging interest in Alzheimer's disease.
Product approaching loss of exclusivity with modest Part D spending ($2M in 2023); brand team focus likely shifting to defended indications or lifecycle extensions.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
Worked on STRATTERA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSTRATTERA represents a mature, non-specialty product with limited current hiring activity, reflecting its LOE status and modest commercial footprint ($2M Part D spend). Career opportunities on this product are primarily defensive and tactical—brand management, market access, and medical liaisons focused on parity vs. generics rather than growth.